

FDA ADVISORY
No. 2022-0473-A

13 MAR 2024

TO: THE GENERAL PUBLIC

SUBJECT: Lifting the Advisory on the Notified Cosmetic Product “HERSKIN REVITA-GLOW SKIN RESCUE KIT; HERSKIN REVITA-GLOW RESCUE REVITALIZING TONER; HERSKIN REVITA-GLOW RESCUE PREMIUM KOJIC COLLAGEN FACIAL SOAP; HERSKIN REVITA-GLOW RESCUE REVITALIZING NIGHT GEL CREAM under FDA Advisory No. 2022-0473 “Public Health Warning Against the Purchase and Use of Unauthorized Cosmetic Product “HERSKIN REVITA-GLOW SKIN RESCUE KIT” dated 08 March 2022

- 1. HERSKIN REVITA-GLOW RESCUE REVITALIZING TONER**
- 2. HERSKIN REVITA-GLOW RESCUE PREMIUM KOJIC COLLAGEN FACIAL SOAP**
- 3. HERSKIN REVITA-GLOW RESCUE REVITALIZING NIGHT GEL CREAM**

The Food and Drug Administration (FDA) informs the public that the following cosmetic products have been notified by the Market Authorization Holder, ARMENDEZ CORP. doing business under the name and style of HerSkin Skincare and Cosmetics, with **Notification Nos. 1000011794690, 1000011794007, and 1000011796784**, in accordance with existing FDA rules and regulations.

HERSKIN REVITA-GLOW SKIN RESCUE KIT:

- 1. HERSKIN REVITA-GLOW RESCUE REVITALIZING TONER**
- 2. HERSKIN REVITA-GLOW RESCUE PREMIUM KOJIC COLLAGEN FACIAL SOAP**
- 3. HERSKIN REVITA-GLOW RESCUE REVITALIZING NIGHT GEL CREAM**

Accordingly, the warning against the purchase and use of the subject product as mentioned in FDA Advisory No. 2022-0473 and its corresponding FDA Order is hereby lifted.

The public is advised to always check if a Cosmetic product is notified with the FDA by using the FDA Verification Portal feature accessible at **<https://verification.fda.gov.ph>** which may be used by typing in the name of the product before purchasing. For more information or inquiries, please email us at **cchuhsrr_prsdd@fda.gov.ph**. You may also call the Center for Cosmetics and Household/Urban Hazardous Substances Regulation and Research at telephone number **(02) 8857-1900 loc. 8113 or 8117**.






To report the sale or distribution of any unnotified/unregistered health products, kindly email FDA via ereport@fda.gov.ph.

Furthermore, the issuance of this advisory shall not in any manner preclude this Office from issuing subsequent orders it may deem necessary and appropriate, should there be findings of any violation of the company to the existing laws, rules, and regulations.

Dissemination of this advisory to all concerned is hereby requested.


DR. SAMUEL A. ZACATE
Director General

DTN 20220123224548

	
 OFELYN C. CABRIDO, RPh, MGM CHIEF, PRSDD, CCHUSRR 	ENGR. ANA TRINIDAD F. RIVERA, MSc Director IV, Center for Cosmetics and Household/Urban Hazardous Substances Regulation and Research